- Red Light Holland (TRIP) has exported 1.5 kg of Psilocybe Truffles from the Netherlands to CCrest Laboratories in Canada
- CCrest will test the suitability of Red Light Holland’s natural psilocybin as a source of active pharmaceutical ingredients for medical purposes
- Red Light Holland completed an initial import with CCrest in March 2021, which has yielded positive results in the first phase of the scientific research
- CCrest Laboratories specializes in researching highly regulated narcotics, including psychedelics
- Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles
- Red Light Holland Corp. (TRIP) opened trading at C$0.25 per share
Red Light Holland (TRIP) has completed another export of high-grade Psilocybe Truffles from the Netherlands to Canada.
The export was authorized under a Health Canada psilocybin import permit awarded to CCrest Laboratories Inc. in partnership with Shaman Pharma Corp.
CCrest Laboratories received 1.5 kg of Red Light Holland’s psilocybe truffles.
The next phase of work in this international collaboration is to evaluate the suitability of Red Light Holland’s natural psilocybin as a source of active pharmaceutical ingredients (API) for scientific and potentially medical purposes.
“I’m absolutely thrilled to have completed a second, even larger import and sale from the Netherlands to Canada. This is just another milestone for Red Light Holland and our loyal shareholders. We continue our path to work within the careful means of the regulatory process with reliable partners in hopes of pushing for safe, responsible access to the company’s naturally occurring psilocybin by testing, learning and educating the public and hopefully Governments right here in Canada and across the world,” said Todd Shapiro, CEO and Director of Red Light Holland.
“We have built a truly phenomenal partnership between Red Light Holland and CCrest Labs, and really value having a true ally and partner with the necessary licenses and permits to bring our products into Canada to test them in a pharma setting. This, alongside our recently announced acquisition of Mera Life Sciences, proves out Red Light Holland’s mandate of pursuing research and development, technology and applied science while spending capital cautiously and responsibly, within the Scarlette Lillie Science and Innovation division.”
CCrest Laboratories, a cGMP pharmaceutical laboratory in Montreal specializing in highly regulated narcotics, including psychedelics, holds a Health Canada Controlled Drugs and Substances License and received federally issued import permits for the restricted drug Psilocybin.
Red Light Holland completed an initial import with CCrest in March 2021, which has yielded positive results in the first phase of the scientific research.
Shaman Pharma, working in conjunction with CCrest Laboratories, is developing cGMP compliant scientific methods and protocols of Quality Control, Analysis and Extraction, aimed at industrial-scale commercialization of medical purpose psychedelic substances in this emerging pharmaceutical sector.
“Considering that, ever since the 60’s prohibition, academia has enjoyed an unmitigated monopoly on psychedelic research, we are extremely proud of our work with Red Light Holland making us the first and only private sector companies known to have achieved repeat international production and shipment of psilocybin truffles,” commented Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories.
“There is only one time to be the world’s first at anything, and we have done it again. Our goal is to keep breaking through these boundaries, to bring the psychedelic renaissance, to advance well-being and mind expansion.”
Once available, Red Light Holland will be excited to share the scientific results with its customers, shareholders, and the expanding psychedelic industry.
Red Light Holland is engaged in the production, growth and sale of a premium brand of magic truffles.
Red Light Holland Corp. (TRIP) opened trading at C$0.25 per share.
